{"url_path":"/sec/alt/8-k/2026-05-13/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1326190/0001326190-26-000037-index.html","accession_number":"0001326190-26-000037","cik":"0001326190","ticker":"ALT","issuer_name":"Altimmune, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1326190/0001326190-26-000037-index.html","primary_entity_key":"0001326190","primary_entity_name":"Altimmune, Inc."},"word_count":113,"has_tables":true,"body_markdown":"**Item 9.01 Financial Statements and Exhibits**\n\n​\n\n(d) Exhibits\n\n​\n\n​\n\n​\n\n**No.**\n\n  ​\n\n**Description**\n\n​\n\n​\n\n​\n\n99.1\n\n​\n\n[Press Release of Altimmune, Inc. dated May 13, 2026](alt-20260513xex99d1.htm)\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n​\n\n​\n\n​\n\n**SIGNATURE**\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n​\n\n​\n\n​\n\n​\n\n​\n\n​\n\n**ALTIMMUNE, INC.**\n\n​\n\n​\n\n​\n\n​\n\n​\n\nBy:\n\n \n\n/s/ Gregory Weaver\n\n​\n\n​\n\n \n\nName: Gregory Weaver\n\n​\n\n​\n\n \n\nTitle: Chief Financial Officer\n\n​\n\nDated: May 13, 2026\n\n​"}